Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 12, 2016, Pages 2324-2333

  Moraes, Leonardo A ^a,b   Unsworth, Amanda J ^a   Vaiyapuri, Sakthivel ^a   Ali, Marfoua S ^a   Sasikumar, Parvathy ^a   Sage, Tanya ^a   Flora, Gagan D ^a   Bye, Alex P ^a   Kriek, Neline ^a   Dorchies, Emilie ^c,d   Molendi Coste, Olivier ^c,d   Dombrowicz, David ^c,d   Staels, Bart ^c,d   Bishop Bailey, David ^e   Gibbins, Jonathan M ^a  

^a UNIVERSITY OF READING   (United Kingdom)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIV LILLE   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

^e ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

blood platelets; farnesoid X activated receptor; fibrinogen; signal transduction; transcription factors

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; ADENOSINE TRIPHOSPHATE; ALPHAIIBBETA3INTEGRIN; CALCIUM; COLLAGEN; CROSS LINKED COLLAGEN RELATED PEPTIDE; CYCLIC GMP; CYCLIC NUCLEOTIDE; FARNESOID X RECEPTOR; FIBRINOGEN; INTEGRIN; OBETICHOLIC ACID; PADGEM PROTEIN; PEPTIDE; THROMBIN; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; ANTITHROMBOCYTIC AGENT; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; FARNESOID X-ACTIVATED RECEPTOR; FIBRINOGEN RECEPTOR; ISOXAZOLE DERIVATIVE; LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOT RETRACTION; BLOOD CLOTTING; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOPLASM; HEMOSTASIS; HUMAN; HUMAN CELL; LASER-INDUCED THROMBOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; C57BL MOUSE; CALCIUM SIGNALING; DEFICIENCY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; GENOTYPE; KNOCKOUT MOUSE; METABOLISM; PHENOTYPE; THROMBOCYTE ACTIVATION; THROMBOSIS; TIME FACTOR;

ANIMALS; BLOOD PLATELETS; CALCIUM SIGNALING; CHENODEOXYCHOLIC ACID; CYCLIC GMP; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOGEN; GENOTYPE; HEMOSTASIS; HUMANS; ISOXAZOLES; LIGANDS; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THROMBOSIS; TIME FACTORS;

EID: 84991478631     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.308093     Document Type: Article

References (52)

1. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW, Evans RM, Weinberger C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995;81:687-693.
2. Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci U S A. 2004;101:3668-3673. doi: 10.1073/pnas.0400046101.
3. Huang W, Ma K, Zhang J, Qatanani M, Cuvillier J, Liu J, Dong B, Huang X, Moore DD. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science. 2006;312:233-236. doi: 10.1126/science.1121435.
4. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, Mangelsdorf DJ, Kliewer SA. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006;103:3920-3925. doi: 10.1073/pnas.0509592103.
5. Li Yoyo TY, Karen ES, Thomas GJ, Warner TD, Bishop-bailey D. Farnesoid X Receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Atheroscler Thromb Vasc Biol. 2007;27:2606-2611.
6. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362-1365.
7. Willson TM, Jones SA, Moore JT, Kliewer SA. Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism. Med Res Rev. 2001;21:513-522.
8. Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, Willson TM. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45:3569-3572.
9. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6:517-526.
10. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell. 2000;6:507-515.
11. Spinelli SL, Maggirwar SB, Blumberg N, Phipps RP. Nuclear emancipation: a platelet tour de force. Sci Signal. 2010;3:pe37. doi: 10.1126/scisignal.3144pe37.
12. Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood. 2003;101:2285-2293. doi: 10.1182/blood-2002-09-2797.
13. Denis MM, Tolley ND, Bunting M, et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell. 2005;122:379-391. doi: 10.1016/j.cell.2005.06.015.
14. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol. 2009;16:961-966. doi: 10.1038/nsmb.1651.
15. Akbiyik F, Ray DM, Gettings KF, Blumberg N, Francis CW, Phipps RP. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40ligand and thromboxanes. Blood. 2004;104:1361-1368. doi: 10.1182/blood-2004-03-0926.
16. Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark M, Bishop-Bailey D, Warner TD, Mitchell JA. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J. 2006;20:326-328. doi: 10.1096/fj.05-4395fje.
17. Moraes LA, Swales KE, Wray JA, Damazo A, Gibbins JM, Warner TD, Bishop-Bailey D. Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood. 2007;109:3741-3744. doi: 10.1182/blood-2006-05-022566.
18. Moraes LA, Paul-Clark MJ, Rickman A, Flower RJ, Goulding NJ, Perretti M. Ligand-specific glucocorticoid receptor activation in human platelets. Blood. 2005;106:4167-4175. doi: 10.1182/blood-2005-04-1723.
19. Spyridon M, Moraes LA, Jones CI, Sage T, Sasikumar P, Bucci G, Gibbins JM. LXR as a novel antithrombotic target. Blood. 2011;117:5751-5761. doi: 10.1182/blood-2010-09-306142.
20. Malaver E, Romaniuk MA, D'Atri LP, Pozner RG, Negrotto S, Benzadón R, Schattner M. NF-kappaB inhibitors impair platelet activation responses. J Thromb Haemost. 2009;7:1333-1343. doi: 10.1111/j.1538-7836.2009.03492.x.
21. Mencarelli A, Renga B, Distrutti E, Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol. 2009;296:H272-H281. doi: 10.1152/ajpheart.01075.2008.
22. Zhang Y, Wang X, Vales C, Lee FY, Lee H, Lusis AJ, Edwards PA. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arterioscler Thromb Vasc Biol. 2006;26:2316-2321. doi: 10.1161/01. ATV.0000235697.35431.05.
23. Kida T, Murata T, Hori M, Ozaki H. Chronic stimulation of farnesoid X receptor impairs nitric oxide sensitivity of vascular smooth muscle. Am J Physiol Heart Circ Physiol. 2009;296:H195-H201. doi: 10.1152/ajpheart.00679.2008.
24. Vaiyapuri S, Jones CI, Sasikumar P, et al. Gap junctions and connexin hemichannels underpin hemostasis and thrombosis. Circulation. 2012;125:2479-2491. doi: 10.1161/CIRCULATIONAHA.112.101246.
25. Moraes LA, Vaiyapuri S, Sasikumar P, Ali MS, Kriek N, Sage T, Gibbins JM. Antithrombotic actions of statins involve PECAM-1 signaling. Blood. 2013;122:3188-3196. doi: 10.1182/blood-2013-04-491845.
26. Shattil SJ, Brass LF. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J Biol Chem. 1987;262:992-1000.
27. Calderwood DA. Integrin activation. J Cell Sci. 2004;117(pt 5):657-666. doi: 10.1242/jcs.01014.
28. Estevez B, Shen B, Du X. Targeting integrin and integrin signaling in treating thrombosis. Arterioscler Thromb Vasc Biol. 2015;35:24-29. doi: 10.1161/ATVBAHA.114.303411.
29. Gao C, Boylan B, Bougie D, Gill JC, Birenbaum J, Newman DK, Aster RH, Newman PJ. Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain. J Clin Invest. 2009;119:504-511. doi: 10.1172/JCI36745.
30. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res. 1989;65:1-21.
31. de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation. 1992;85:2284-2290.
32. Spurgeon BE, Aburima A, Oberprieler NG, Taskén K, Naseem KM. Multiplexed phosphospecific flow cytometry enables large-scale signaling profiling and drug screening in blood platelets. J Thromb Haemost. 2014;12:1733-1743. doi: 10.1111/jth.12670.
33. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol. 2001;62:1153-1161.
34. Wentworth JK, Pula G, Poole AW. Vasodilator-stimulated phosphoprotein (VASP) is phosphorylated on Ser157 by protein kinase C-dependent and -independent mechanisms in thrombin-stimulated human platelets. Biochem J. 2006;393(pt 2):555-564. doi: 10.1042/BJ20050796.
35. Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res. 2012;53:1723-1737. doi: 10.1194/jlr.R024794.
36. Gibbins JM. Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci. 2004;117(pt 16):3415-3425. doi: 10.1242/jcs.01325.
37. Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov. 2003;2:775-789. doi: 10.1038/nrd1198.
38. Mencarelli A, Fiorucci S. FXR an emerging therapeutic target for the treatment of atherosclerosis. J Cell Mol Med. 2010;14:79-92. doi: 10.1111/j.1582-4934.2009.00997.x.
39. Moraes LA, Spyridon M, Kaiser WJ, Jones CI, Sage T, Atherton RE, Gibbins JM. Non-genomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation. J Thromb Haemost. 2010;8:577-587. doi: 10.1111/j.1538-7836.2009.03732.x.
40. Zhang R, Ran HH, Zhang YX, Liu P, Lu CY, Xu Q, Huang Y. Farnesoid X receptor regulates vascular reactivity through nitric oxide mechanism. J Physiol Pharmacol. 2012;63:367-372.
41. Li J, Wilson A, Kuruba R, Zhang Q, Gao X, He F, Zhang LM, Pitt BR, Xie W, Li S. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc Res. 2008;77:169-177. doi: 10.1093/cvr/cvm016.
42. Li Z, Xi X, Gu M, Feil R, Ye RD, Eigenthaler M, Hofmann F, Du X. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell. 2003;112:77-86.
43. Marjanovic JA, Li Z, Stojanovic A, Du X. Stimulatory roles of nitricoxide synthase 3 and guanylyl cyclase in platelet activation. J Biol Chem. 2005;280:37430-37438. doi: 10.1074/jbc.M506518200.
44. Gambaryan S, Kobsar A, Hartmann S, Birschmann I, Kuhlencordt PJ, Müller-Esterl W, Lohmann SM, Walter U. NO-synthase-/NO-independent regulation of human and murine platelet soluble guanylyl cyclase activity. J Thromb Haemost. 2008;6:1376-1384. doi: 10.1111/j.1538-7836.2008.03014.x.
45. Ozüyaman B, Gödecke A, Küsters S, Kirchhoff E, Scharf RE, Schrader J. Endothelial nitric oxide synthase plays a minor role in inhibition of arterial thrombus formation. Thromb Haemost. 2005;93:1161-1167. doi: 10.1160/TH03-09-0588.
46. Prawitt J, Abdelkarim M, Stroeve JH, et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes. 2011;60:1861-1871. doi: 10.2337/db11-0030.
47. Shamir R, Johnson WJ, Morlock-Fitzpatrick K, Zolfaghari R, Li L, Mas E, Lombardo D, Morel DW, Fisher EA. Pancreatic carboxyl ester lipase: a circulating enzyme that modifies normal and oxidized lipoproteins in vitro. J Clin Invest. 1996;97:1696-1704. doi: 10.1172/JCI118596.
48. Burkard I, von Eckardstein A, Rentsch KM. Differentiated quantification of human bile acids in serum by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;826:147-159. doi: 10.1016/j.jchromb.2005.08.016.
49. Shiao YJ, Chen JC, Wang CN, Wang CT. The mode of action of primary bile salts on human platelets. Biochim Biophys Acta. 1993;1146 :282-293.
50. Wiener G, Moore HB, Moore EE, Gonzalez E, Diamond S, Zhu S, D'Alessandro A, Banerjee A. Shock releases bile acid inducing platelet inhibition and fibrinolysis. J Surg Res. 2015;195:390-395. doi: 10.1016/j. jss.2015.01.046.
51. Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J Lipid Res. 2009;50:1090-1100. doi: 10.1194/jlr.M800619-JLR200.
52. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102:731-744.